Cellectis S.A. (NASDAQ:CLLS – Get Rating)’s share price passed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $1.92 and traded as low as $1.75. Cellectis shares last traded at $1.78, with a volume of 34,124 shares traded.
Analyst Ratings Changes
Several equities analysts have commented on CLLS shares. Oppenheimer lowered their target price on shares of Cellectis from $16.00 to $13.00 and set an “outperform” rating on the stock in a research report on Monday, March 13th. Citigroup lowered their price target on Cellectis from $24.00 to $16.00 and set a “buy” rating on the stock in a research report on Wednesday, April 5th. JMP Securities reaffirmed a “market outperform” rating and issued a $6.00 price target on shares of Cellectis in a research report on Monday, March 13th. StockNews.com initiated coverage on Cellectis in a research report on Thursday, May 18th. They issued a “hold” rating on the stock. Finally, Bryan, Garnier & Co initiated coverage on Cellectis in a research report on Friday, March 17th. They issued a “buy” rating and a $6.00 price target on the stock. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $10.25.
Cellectis Trading Up 3.5 %
The company has a debt-to-equity ratio of 0.16, a current ratio of 2.27 and a quick ratio of 2.27. The company’s 50 day moving average is $1.92 and its two-hundred day moving average is $2.25. The firm has a market cap of $98.93 million, a P/E ratio of -0.80 and a beta of 2.12.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Baird Financial Group Inc. bought a new position in Cellectis during the third quarter worth about $74,000. Virtu Financial LLC bought a new position in Cellectis during the second quarter worth about $46,000. OLD Mission Capital LLC lifted its stake in Cellectis by 90.0% during the first quarter. OLD Mission Capital LLC now owns 22,329 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 10,577 shares during the period. Balyasny Asset Management LLC bought a new position in Cellectis during the third quarter worth about $42,000. Finally, Two Sigma Investments LP bought a new position in shares of Cellectis in the third quarter valued at approximately $30,000. Institutional investors own 22.61% of the company’s stock.
Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.
- Get a free copy of the StockNews.com research report on Cellectis (CLLS)
- Ralph Lauren’s Styled Dividend Is Still In Season
- Dollar Tree Falls As Theft Cuts Into Bottom Line
- Best Buy’s Comeback Is Still At Play, Earnings Call For Patience
- e.l.f. Beauty Has Giant Quarter, Shares Hit New High
- If You Can Only Pick One Stock For The Rest Of 2023, Pick Nvidia
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.